RxDoctor Payments DataLook up a doctor →

Efrain Garcia, MD

Infectious Disease · Miami, FLNPI 1447239496

Payments from drug & device makers

$2,478,557in general payments, 2019–2025

Across 395 payments — averaging $6274.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$2.3M
  • Merck$106K
  • Sanofi US Services Inc.$15K
  • AstraZeneca$13K
  • Viiv Healthcare Company$8K
  • Gilead$7K
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$11,49068%
  • Speaking & faculty fees$150%
  • Food & beverage$5,29131%
  • Education$1501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,478,557 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$23,300
Medicare patients
62
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala272$1,181,254
SerostimSomatropin25$502,539
TriumeqAbacavir/Dolutegravir/Lamivudi47$174,933
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf31$149,361
TivicayDolutegravir Sodium43$125,051
JulucaDolutegravir/Rilpivirine33$120,894
PrezcobixDarunavir/Cobicistat24$88,831
CabenuvaCabotegravir/Rilpivirine12$80,188
DovatoDolutegravir Sodium/Lamivudine21$63,992
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$49,187
MytesiCrofelemer11$31,189
MounjaroTirzepatide22$23,045
VascepaIcosapent Ethyl66$22,127
ValacyclovirValacyclovir Hcl72$3,698
Testosterone Cypionate65$1,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$6,870$1,181,254272 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Juluca, Cabenuva, Dovato$8,120$565,057156 claims
EMD Serono, Inc.Serostim$85$502,53925 claims
Janssen Products, LPSymtuza$150$149,36131 claims
Johnson & JohnsonPrezcobix$607$88,83124 claims
Napo Pharmaceuticals IncMytesi$71$31,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →